Search results for "MEL"

showing 10 items of 6009 documents

Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre st…

2016

Ajuda rebuda: GlaxoSmithKline Several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) have been made recently available in Spain for type 2 diabetes mellitus (DM2) treatment. There are no published data on the clinical and sociodemographic profile of patients initiating treatment with GLP-1Ra in Spain. Our objective was to understand these patients' characteristics in a real-world clinical practice setting. Design. Cross-sectional observational study. Setting. Spanish specialist outpatient clinics.Participants 403 adults with DM2 initiating GLP-1Ra treatment were included. Primary and secondary outcome measures Sociodemographic and DM2-related clinical data, including treatment …

medicine.medical_specialtyDM2Cross-sectional studymedicine.medical_treatment030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineInsulinaInternal medicinemedicineOutpatient clinic030212 general & internal medicineMedical prescriptionGlucagon-like peptide 1 receptorDiabetisbusiness.industryInsulinDiabetis mellitus tipus 2Type 2 Diabetes MellitusGeneral MedicineDiabetes mellitus tipo 2EndocrinologyConcomitantMalalties d'origen nutricionalbusinessBody mass index
researchProduct

A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes

2015

Contains fulltext : 152084.pdf (Publisher’s version ) (Open Access) BACKGROUND: Optimal glucose-lowering therapy in type 2 diabetes mellitus requires a patient-specific approach. Although a good framework, current guidelines are insufficiently detailed to address the different phenotypes and individual needs of patients seen in daily practice. We developed a patient-specific decision support tool based on a systematic analysis of expert opinion. MATERIALS AND METHODS: Based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) 2012 position statement, a panel of 12 European experts rated the appropriateness (RAND/UCLA Appropriateness Method) of tre…

medicine.medical_specialtyDecision support systemEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]MEDLINEType 2 diabetesComorbidityHypoglycemiaGlucagon-Like Peptide-1 ReceptorBody Mass IndexEndocrinologyLife ExpectancyClinical ProtocolsInternal medicineHealth careReceptors GlucagonMedicineHumansHypoglycemic AgentsInsulinPrecision MedicineIntensive care medicineExpert TestimonyReimbursementComputingMilieux_MISCELLANEOUSGlycated HemoglobinDipeptidyl-Peptidase IV InhibitorsPioglitazonebusiness.industryDrug SubstitutionType 2 Diabetes MellitusMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]Original ArticlesPrecision medicinemedicine.diseaseDecision Support Systems ClinicalHypoglycemiaMetformin3. Good healthEuropeMedical Laboratory TechnologyEndocrinologySulfonylurea CompoundsDiabetes Mellitus Type 2Drug Therapy CombinationThiazolidinedionesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Accuracy of computer-aided image analysis in the diagnosis of odontogenic cysts: A systematic review

2020

Background This study aimed to search for scientific evidence concerning the accuracy of computer-assisted analysis for diagnosing odontogenic cysts. Material and Methods A systematic review was conducted according to the PRISMA statements and considering eleven databases, including the grey literature. Protocol was registered in PROSPERO (CRD 42020189349). The PECO strategy was used to define the eligibility criteria and only studies involving diagnostic accuracy were included. Their risk of bias was investigated using the Joanna Briggs Institute Critical Appraisal tool. Results Out of 437 identified citations, five papers, published between 2006 and 2019, fulfilled the criteria and were i…

medicine.medical_specialtyDentigerous CystMEDLINEOdontogenic TumorsReviewmelanomamedicineGlandular odontogenic cystHumansKeratocystGeneral DentistryUNESCO:CIENCIAS MÉDICASRadicular CystRadicular CystOral Medicine and Pathologyoral mucosabusiness.industryComputersLateral periodontal cystmedicine.diseaseoral melanomaDentigerous cystCritical appraisalOtorhinolaryngologyMeta-analysisOdontogenic Cystshead and neck cancerSurgeryRadiologymedicine.symptombusinessMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

A case report of desmoplastic ameloblastoma

2010

Ameloblastomas are the most common benign neoplasm of odontogenic nature. Desmoplastic ameloblastoma (DA) was included in the World Health Organization Classification of Head and Neck Tumors (WHO-2005) as a variant of ameloblastoma with specific clinical, image, and histological features. This case report focuses on a DA which occurred in the mandible of a 25 year-old man. The main signals and symptoms included painless swelling with buccal expansion and tooth displacement. Panoramic and periapical radiographs and cone-bean computed to- mography demonstrated an image mimicking a benign fibro-osseous lesion. The lower border of the mandible was not involved, but tooth displacement could be o…

medicine.medical_specialtyDesmoplastic ameloblastomabusiness.industryHead and neck tumorsMandibleOdontología:CIENCIAS MÉDICAS [UNESCO]Marginal resectionmedicine.diseaseCiencias de la saludWorld healthSurgeryLesionstomatognathic diseasesUNESCO::CIENCIAS MÉDICASmedicineDisplacement (orthopedic surgery)medicine.symptombusinessAmeloblastomaGeneral DentistryJournal of Clinical and Experimental Dentistry
researchProduct

Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency

2019

Background Dual-release hydrocortisone (DR-HC) improves metabolism in patients with adrenal insufficiency. The aims of this study were to compare the cardiovascular and metabolic effects of conventional glucocorticoids (GCs) vs. DR-HC and of high vs. low doses of GCs, after 48 months of observation. Methods We selected 27 patients on hydrocortisone (mean dose 17.5 ± 4.2 mg/day) and 20 patients on cortisone acetate (mean dose 37.5 ± 12.1 mg/day) who maintained this treatment (group A) and 53 patients switched to DR-HC (mean dose 22 ± 4.8 mg/day) (group B). At baseline and after 48 months, clinical and metabolic parameters and Framingham Risk Score (FRS) were obtained. Results After 48 month…

medicine.medical_specialtyDiabetes mellituWaistDual releaseEndocrinology Diabetes and MetabolismUrology030209 endocrinology & metabolismlcsh:Diseases of the endocrine glands. Clinical endocrinologyConventional glucocorticoidGroup BSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal MedicineAdrenal insufficiencymedicineHydrocortisonelcsh:RC648-665Framingham Risk Scorebusiness.industryResearchconventional glucocorticoidsmedicine.diseaseCardiovascular riskBlood pressure030220 oncology & carcinogenesisdiabetes mellitusDual-release hydrocortisonebusinessAdrenal insufficiencymedicine.drug
researchProduct

SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class

2019

Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion To debate newly available CVOT data and to put them into…

medicine.medical_specialtyDiabetes mellitus type 2 ; drug therapy ; Cardiovascular diseases ; drug therapy ; Canagliflozin ; therapeutic use ; Benzhydryl compounds ; therapeutic use ; Glucosides ; therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors ; therapeutic useEndocrinology Diabetes and MetabolismEmpagliflozin610 Medicine & health030209 endocrinology & metabolismContext (language use)ComorbidityType 2 diabetesDiseaseCanagliflozin ; Cardiovascular disease ; Dapagliflozin ; Empagliflozin ; SGLT2 inhibitor ; Type 2 diabetes.lcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusCorrespondenceEmpagliflozinHumansMedicine030212 general & internal medicineCanagliflozinDapagliflozinIntensive care medicineSodium-Glucose Transporter 2 InhibitorsCanagliflozinlcsh:RC648-665business.industryIncidence616.379-008.64 [udc]Type 2 diabetesSGLT2 inhibitorGeneral MedicineDapagliflozinCardiovascular diseasePrognosismedicine.disease3. Good healthEastern europeanDiabetes Mellitus Type 2chemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

Use of the Diabetes Risk Score for Opportunistic Screening of Undiagnosed Diabetes and Impaired Glucose Tolerance

2005

OBJECTIVE—To evaluate an opportunistic screening strategy addressed to individuals with one or more cardiovascular risk factor, based on the Diabetes Risk Score (DRS) as the initial instrument, for the identification of individuals with type 2 diabetes or impaired glucose tolerance (IGT). RESEARCH DESIGN AND METHODS—The DRS, a simple self-administered questionnaire, was completed by individuals identified by general practitioners and presenting with one or more cardiovascular risk factor. All patients underwent a 2-h oral glucose tolerance test (OGTT). The optimal DRS cutoff was calculated by applying the receiver-operating characteristic curve. RESULTS—Overall, 1,377 individuals aged betwe…

medicine.medical_specialtyDiabetes riskEndocrinology Diabetes and MetabolismType 2 diabetesImpaired glucose toleranceMELLITUSNIDDMPEOPLEInternal medicineDiabetes mellitusInternal MedicinemedicineRisk factorProspective cohort studyAdvanced and Specialized NursingGlucose tolerance testmedicine.diagnostic_testbusiness.industryPERFORMANCEmedicine.diseaseImpaired fasting glucosePREVENTIONPREVALENCEEndocrinologyLIFE-STYLEHEALTHbusinessDiabetes Care
researchProduct

Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance

2007

Type 2 diabetes is characterized by cellular and extracellular Mg depletion. Epidemiologic studies showed a high prevalence of hypomagnesaemia and lower intracellular Mg concentrations in diabetic subjects. Insulin and glucose are important regulators of Mg metabolism. Intracellular Mg plays a key role in regulating insulin action, insulin-mediated-glucose uptake and vascular tone. Reduced intracellular Mg concentrations result in a defective tyrosine-kinase activity, post-receptorial impairment in insulin action, and worsening of insulin resistance in diabetic patients. Mg deficit has been proposed as a possible underlying common mechanism of the "insulin resistance" of different metabolic…

medicine.medical_specialtyDiabetes riskmedicine.medical_treatmentBiophysicsType 2 diabetesBiochemistryInsulin resistanceDiabetes mellitusInternal medicineHumansInsulinMedicineMagnesiumMolecular BiologyMetabolic Syndromebusiness.industryInsulinType 2 Diabetes Mellitusmedicine.diseaseGlucoseEndocrinologyDiabetes Mellitus Type 2Insulin ResistanceMetabolic syndromebusinessIntracellularArchives of Biochemistry and Biophysics
researchProduct

Comparative characteristics of older people with type 1 diabetes treated with continuous subcutaneous insulin infusion or insulin injection therapy :…

2019

Aim To compare clinical characteristics and outcomes in adults with type 1 diabetes aged ≥ 60 years using continuous subcutaneous insulin infusion (CSII) vs. insulin injection therapy. Further, to determine the percentage of older adults with type 1 diabetes using CSII. Research design and methods Retrospective study using data of the Diabetes Prospective Follow-up Registry (DPV). Including percentage CSII use from 2008 to 2018, and the characteristics of 9547 individuals extracted from the DPV in March 2019 (N = 1404 CSII; N = 8143 insulin injection therapy). Wilcoxon rank sum tests were used for continuous variables and chi-square tests for categorical variables to compare clinical charac…

medicine.medical_specialtyDiabetic ketoacidosisEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal medicineDiabetes mellitus Type 1Internal MedicineMedicine030212 general & internal medicineddc:610ContraindicationDepression (differential diagnoses)AgedType 1 diabetesbusiness.industryInsulinCSIIDiabetes mellitus; TherapyDiabetes mellitus Typ 1Retrospective cohort studymedicine.diseaseInsulin infusion systems3. Good healthMicroalbuminuriaOlder peopleInsulinpumpebusinessAlter <60-90 Jahre>
researchProduct

Diabetes Mellitus and Ramadan: Physiopathological, Clinical and Therapeutic Aspects

2017

Fasting from dawn to sunset during Ramadan is one of the five pillars of Islam. A significant number of diabetic patients insist on fasting during Ramadan against the recommendations of their physicians. Fasting in diabetic subjects may be associated with increased risk of hypoglycemia and hyperglycemia, diabetic ketoacidosis, dehydration and thrombosis. Patients with uncontrolled diabetes mellitus are predisposed to major metabolic risks. Another problem is the reluctance of diabetic patients in taking their medications during the fast; therefore the timing and the dosage of anti-diabetic drugs must be adapted for each patient. It is important for diabetic patients who wish to fast during …

medicine.medical_specialtyDiabetic ketoacidosisHealth professionalsbusiness.industryHypoglycemiamedicine.diseaseThrombosisIncreased riskEndocrinologyInternal medicineDiabetes mellitusMedicineDiabetic patientbusinessIntensive care medicineInternational Journal of Advanced Nutritional and Health Science
researchProduct